United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary ENDOLOGIX REPORTS 2005 SECOND QUARTER RESULTS
Conference Call to Begin at 5:00 p.m. ET/2:00 p.m. PT Today
View HTML
Toggle Summary ENDOLOGIX APPROVED TO CONDUCT POWERLINK CLINICAL TRIALS ON PATIENTS WITH LARGE DIAMETER ANEURYSM NECKS
ENDOLOGIX APPROVED TO CONDUCT POWERLINK CLINICAL TRIALS ON PATIENTS WITH LARGE DIAMETER ANEURYSM NECKS IRVINE, Calif. (July 26, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to enroll patients in its
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL
ENDOLOGIX ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL Irvine, Calif. – July 21, 2005 – Endologix, Inc. (Nasdaq: ELGX) , the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the
View HTML
Toggle Summary ENDOLOGIX COMPLETES $16.6 MILLION PRIVATE PLACEMENT
ENDOLOGIX COMPLETES $16.6 MILLION PRIVATE PLACEMENT Irvine, Calif. – July 8, 2005 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced the completion of a previously announced
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT
ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT Irvine, Calif. – July 6, 2005 – Endologix, Inc. (Nasdaq: ELGX), the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive
View HTML
Toggle Summary ENDOLOGIX SCHEDULED TO JOIN THE NEW RUSSELL MICROCAP INDEX
ENDOLOGIX SCHEDULED TO JOIN THE NEW RUSSELL MICROCAP INDEX IRVINE, Calif. (June 14, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that it is scheduled to join the new Russell Microcap™ Index when the Russell Investment Group reconstitutes its family of U.S. indexes on June 24.
View HTML
Toggle Summary ENDOLOGIX’S POWERLINK SYSTEM GRANTED CANADIAN APPROVAL
ENDOLOGIX’S POWERLINK SYSTEM GRANTED CANADIAN APPROVAL IRVINE, Calif. (June 9, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that it has been granted approval (Notice of Compliance) on May 27, 2005, by the Canadian Regulatory Agency, Health Canada Therapeutic Products
View HTML
Toggle Summary ENDOLOGIX PROVIDES JAPANESE REGULATORY UPDATE
Company Plans Japanese Powerlink Submission Supplemented by PowerWeb Data
View HTML
Toggle Summary ENDOLOGIX REPORTS 2005 FIRST QUARTER RESULTS
Irvine, Calif. – April 25, 2005 – Endologix, Inc. (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAA), today announced financial results for the quarter ended
View HTML
Toggle Summary ENDOLOGIX REPORTS 2004 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
ENDOLOGIX REPORTS 2004 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS IRVINE, Calif. (March 14, 2005) Endologix, Inc. (NASDAQ: ELGX) , developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAA),
View HTML
Toggle Summary ENDOLOGIX TO PRESENT AT WELLS FARGO SECURITIES HEALTHCARE CONFERENCE
Webcast Scheduled March 1 at 10:30 p.m. ET
View HTML
Toggle Summary ENDOLOGIX APPOINTS HERBERT H. MERTENS VICE PRESIDENT OF SALES AND MARKETING
ENDOLOGIX APPOINTS HERBERT H. MERTENS VICE PRESIDENT OF SALES AND MARKETING IRVINE, Calif. (February 1, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced the appointment of Herbert H. Mertens to the newly created position of vice president of sales and marketing. He will oversee the U.S.
View HTML
Toggle Summary ENDOLOGIX NAMES RONALD H. COELYN TO BOARD OF DIRECTORS
ENDOLOGIX NAMES RONALD H. COELYN TO BOARD OF DIRECTORS IRVINE, Calif. (January 28, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that Ronald H. Coelyn has been appointed to its board of directors as an independent director, bringing Endologix board membership to eight.
View HTML
Toggle Summary ENDOLOGIX PRESENTS CLINICAL DATA AT INTERNATIONAL SYMPOSIUM OF ENDOVASCULAR THERAPY
Three-Year Preliminary Data Analysis Following Powerlink® Procedure Suggests Decreases in Aneurysm Sac Diameter and Volume
View HTML
Toggle Summary CRYOLIFE AND ENDOLOGIX SIGN DEVELOPMENT AGREEMENT FOR BIOFOAM
Endologix to develop CryoLife’s innovative, self-expanding sealant as a filling agent for aortic aneurysms
View HTML